Viral Infection
68
15
17
32
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.4%
3 terminated out of 68 trials
91.4%
+4.9% vs benchmark
7%
5 trials in Phase 3/4
22%
7 of 32 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 32 completed trials
Clinical Trials (68)
Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)
Viromes in Infants Presenting With a Septic Syndrome
Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
Effects of Mouthrinse on the Microbiome of the Oral Cavity and GI Tract
Donor-Derived Viral Specific T-cells (VSTs)
Third Party Viral Specific T-cells (VSTs)
School Inner City Air Study
Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Department (RADIATE)
Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis
REVIVe: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI
Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway
Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis
Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)
Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection
Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO
COMPArative Study of the Consequence on innaTe Immune Response du to Bacterial or Viral Infection in Patients Admitted to Intensive Care Unit